Description |
Product Type |
Product Size |
Tablets |
30'S |
Product Company |
PMS Pharma |
Letrozole 2.5mg |
Product Type |
Product Size |
Capsules |
100'S |
Product Company |
Pharmedic |
Hydroxyurea 500mg |
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Roche Pharma |
Pertuzumab 420mg/14ml |
Product Type |
Product Size |
Tablets |
28'S |
Product Company |
Himmel Pharma |
Bicalutamide 50mg |
Product Type |
Product Size |
Tablet |
10'S |
Product Company |
Martin Dow |
Ondansetron 8mg |
Product Type |
Product Size |
Tablet |
60'S |
Product Company |
Pharma Solution |
Sorafenib 500mg |
Content | Letrozole is a medicine used for treating breast cancer. It can also help prevent breast cancer coming back. It is mainly prescribed for women who have been through the menopause and have a type of cancer called "hormone-dependent" breast cancer.
| Hydroxyurea is in a class of medications called antimetabolites. Hydroxyurea treats cancer by slowing or stopping the growth of cancer cells in your body. Hydroxyurea treats sickle cell anemia by helping to prevent formation of sickle-shaped red blood cells. | "
Pertuzumab is a monoclonal antibody. . Monoclonal antibodies work by attaching to proteins on or in cancer cells. Human epidermal growth factor 2 (HER2) is a protein that makes cells grow and divide. | Bicalutamide belongs to the group of medicines called antiandrogens. It works by blocking the effects of testosterone (a male hormone), which helps stop the growth and spread of cancer cells.
| Ondansetron is one of the medications most commonly used for the empiric treatment of nausea and vomiting. Ondansetron has excellent utility as an antiemetic drug, and it is effective against nausea and vomiting of various etiologies. | Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body.
|
Reviews
There are no reviews yet.